


novosomAG®



ChiroBlock® GmbH

Press Contact:

For novosom AG
Gerold Endert

For ChiroBlock GmbH
Oliver Seidelmann

Chiroblock and novosom complete lipid synthesis program

Halle and Wolfen, Germany - July10th, 2007

Chiroblock GmbH, Wolfen has completed a comprehensive lipid synthesis program for novosom AG. The Wolfen, Germany based chemical synthesis specialist completed delivery of numerous structurally novel lipids to Novosom AG, Halle, Germany.

Dr. Steffen Panzner, CSO of novosom AG said: "Novosom has ordered a larger collection of individual lipids to feed our continuous research efforts in the field of carrier development for oligonucleotide delivery. When it came to the synthesis part, we were clearly aware of Chiroblock's outstanding performance and reliability in the field of chemical synthesis. All compounds were delivered to schedule and the novel material allows novosom to fully go ahead with comprehensive screening activities."

Dr. Oliver Seidelmann, ChiroBlock, said, "With Novosom we are sharing a longstanding relationship in the field of lipid synthesis. We are encouraged by

the recent success of the lipid synthesis program and are looking forward to see compounds from the existing pipeline moving towards development and eventual clinical use. Altogether - this collaboration is another excellent example of the mutual benefits of chemical outsourcing to highly specialized partners from sponsors pursuing their own demanding aims which are based on new, exclusive molecules.”

About Novosom AG

Novosom is working with its partners to develop unique antisense, DNAi and siRNA based therapeutics with a current focus in inflammation, oncology and liver diseases. Novosom's Smarticles® liposomal vectors allow partners to deliver their active substance (siRNA, antisense, decoy etc) inside the cell either for topical or systemic applications. Smarticles are an enabler of systemic treatments and an enhancer of topical treatments. The Company has several active therapeutically-relevant collaborations in oncology and inflammation. Novosom AG main investors include IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH and MBG Mittelständische Beteiligungs-gesellschaft Sachsen Anhalt.

Novosom AG is based in Halle, Germany. For more information, please visit: www.novosom.com.

About Chiroblock GmbH

ChiroBlock is a research based chemical company offering both exclusive and non-exclusive research reagents and synthetic procedures for customers requiring profound external chemistry expertise. The company is focused on chiral or otherwise sophisticated molecules. ChiroBlock's contract customers, mainly researchers of life-science companies, benefit from the lean, entirely service orientated structure with modern systems for managing projects, knowledge, risks and quality. With the unique approach to economically offer research quantities of exclusive compounds, ChiroBlock as a chemical CRO, fills the gap between basic research and applied chemical development. During the last eight years, ChiroBlock has been developed to become the ideal outsourcing partner for innovative customers requiring new molecules, new syntheses or new chemicals with custom tailored properties on time.

ChiroBlock GmbH is based in Wolfen, Germany. For more information, please visit: www.chiroblock.com